[go: up one dir, main page]

IL162268A0 - Tempamine compositions and methods of use - Google Patents

Tempamine compositions and methods of use

Info

Publication number
IL162268A0
IL162268A0 IL16226802A IL16226802A IL162268A0 IL 162268 A0 IL162268 A0 IL 162268A0 IL 16226802 A IL16226802 A IL 16226802A IL 16226802 A IL16226802 A IL 16226802A IL 162268 A0 IL162268 A0 IL 162268A0
Authority
IL
Israel
Prior art keywords
tempamine
compositions
methods
blood circulation
circulation lifetime
Prior art date
Application number
IL16226802A
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of IL162268A0 publication Critical patent/IL162268A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)

Abstract

A therapeutic composition comprised of tempamine for treatment of conditions caused by oxidative stress or cellular oxidative damage is described. In one embodiment, the tempamine is administered in a vehicle suitable to extend its blood circulation lifetime. For example, tempamine is loaded into the liposomes that provide an extended blood circulation lifetime for effective therapy against inflammation or cell proliferation.
IL16226802A 2001-12-06 2002-12-06 Tempamine compositions and methods of use IL162268A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33804601P 2001-12-06 2001-12-06
PCT/US2002/039261 WO2003053442A1 (en) 2001-12-06 2002-12-06 Tempamine compositions and methods of use

Publications (1)

Publication Number Publication Date
IL162268A0 true IL162268A0 (en) 2005-11-20

Family

ID=23323178

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16226802A IL162268A0 (en) 2001-12-06 2002-12-06 Tempamine compositions and methods of use

Country Status (8)

Country Link
US (1) US20040219201A1 (en)
EP (1) EP1453508B1 (en)
JP (1) JP2005513104A (en)
AT (1) ATE551058T1 (en)
AU (1) AU2002351316B2 (en)
CA (1) CA2469047A1 (en)
IL (1) IL162268A0 (en)
WO (1) WO2003053442A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523413A1 (en) 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
JP2005321669A (en) * 2004-05-11 2005-11-17 Pentax Corp Optical communication apparatus
EP1793805A1 (en) * 2004-09-09 2007-06-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions
WO2006027786A2 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of liposomal glucocorticoids for treating inflammatory states
WO2013114377A1 (en) 2012-02-02 2013-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Stable liposomes for drug delivery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
JPS6442418A (en) * 1985-12-06 1989-02-14 Yissum Res Dev Co Liposome/anthraquinone drug composition and therapy therewith
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5527528A (en) * 1989-10-20 1996-06-18 Sequus Pharmaceuticals, Inc. Solid-tumor treatment method
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0787492B1 (en) * 1990-03-16 2003-09-17 THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE Use of nitroxides and oxazolidines for protection against ionising radiation and oxidative stress
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5972379A (en) * 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
EP0906078B1 (en) * 1996-05-07 2003-11-12 Eric F. Bernstein Topical use of tempol in the prevention of photoaging
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US5827532A (en) * 1997-01-31 1998-10-27 The Reagents Of The University Of California Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
WO1998053835A1 (en) * 1997-05-27 1998-12-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
US6410680B1 (en) * 2000-06-21 2002-06-25 Dendrimolecular, Inc. Dendrimer constructs and metal complexes thereof having superoxide dismutase activity
AU2001293064A1 (en) * 2000-09-26 2002-04-08 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal

Also Published As

Publication number Publication date
WO2003053442A1 (en) 2003-07-03
US20040219201A1 (en) 2004-11-04
EP1453508B1 (en) 2012-03-28
EP1453508A1 (en) 2004-09-08
AU2002351316B2 (en) 2008-01-31
JP2005513104A (en) 2005-05-12
CA2469047A1 (en) 2003-07-03
AU2002351316A1 (en) 2003-07-09
ATE551058T1 (en) 2012-04-15

Similar Documents

Publication Publication Date Title
GB9807639D0 (en) Anti-inflammatory agents
EA200500149A1 (en) Tissue Protective Cytokines for the Protection, Restoration and Stimulation of Reactive Cells, Tissues and Organs
ES2187785T3 (en) 3,5-DIFENIL-1,2,4-SUBSTITUTED TRIAZOLS AND ITS USE AS PHARMACEUTICAL METAL BURNERS.
CY1116463T1 (en) Combination therapy for the therapeutic treatment of Protein Deficiency Disorders
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
ATE380548T1 (en) USE OF P53 INHIBITORS FOR THE TREATMENT OF ADVERSE SYMPTOMS OF CANCER THERAPY
BR0212252A (en) Methods to Reduce Hypertension and Heart Failure in a Mammal
FI953748A0 (en) Compounds with both potent calcium antagonist and antioxidant activity and their use as cell protective agents
WO2004093831A3 (en) Cytokine-expressing cellular vaccine combinations
DK1239849T3 (en) Pharmaceutical formulations comprising resveratrol and its use
DK0933995T3 (en) Procedure for the treatment of endothelial damage
NZ541593A (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
SE9900961D0 (en) Novel compounds
DE602004018944D1 (en) USE OF SUPPLEMENT FOR TREATMENT OF IRRITATION SYNDROME
NZ513096A (en) Compositions for treating inflammatory response
BRPI0418157A (en) allogeneic tumor therapy
ATE368455T1 (en) USE OF (+)-TRAMADOL, O-DEMETHYLTRAMADOL, O-DESMETHYL-N-MONO-DESMETHYL-TRAMADOL FOR THE THERAPY OF URINARY INCONTINENCE
WO2002017898A3 (en) Compositions and methods for inducing vasorelaxation
DE60140960D1 (en) USE OF SERP-1 IN COMBINATION WITH AN IMMUNOSUP PRESSOR FOR THE TREATMENT OF ARTHRITIS
EA200501828A1 (en) TISSUE PROTECTOR CYTOKINES WITH ENLARGED THERAPEUTIC WINDOW FOR PROTECTION, RESTORATION AND STIMULATION OF REACTIVE CELLS, TISSUES AND BODIES
IL162268A0 (en) Tempamine compositions and methods of use
DE60232154D1 (en) PROPHYLACTIC AND THERAPEUTIC USE OF HYDROXYSTEROIDS
AR027677A1 (en) A THERAPEUTIC PHARMACEUTICAL COMPOSITION THAT INCLUDES CAMPTOTECHINE AND CYCLOFOSPHAMIDE FOR THE TREATMENT OF CANCER